{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.96","value":"69.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"Summarized with mean and standard deviation for those with available data in Arm C","dispersionType":"Standard Deviation","groups":[{"description":"Arm C (Safety and Efficacy), IR/HR MLL-R chemotherapy and lestaurtinib at DL2 (HR: 4.25 mg/kg/day; SR: 5 mg/kg/day)","id":"OG000","title":"Arm C (Safety/Efficacy Dose Level 2)"}],"paramType":"MEAN","populationDescription":"Arm C Dose Level 2 (DL2) patients who had data available for analysis.","reportingStatus":"POSTED","timeFrame":"Sampled between weeks 6-12 from start of induction","title":"Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy","type":"SECONDARY","unitOfMeasure":"Activity percentage"}